In Silico Discovery of Novel CDK1 Inhibitors from Linum Species for Targeted Cancer Therapy
By: Ryma Mouna and Abdalwahab Ahmed
References
- Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46.
- Bower JJ, Vance LD, Psioda M, et al. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. npj Breast Cancer 2017 31. 2017;3(1):1–12.
- Dalton S. Linking the Cell Cycle to Cell Fate Decisions. Trends Cell Biol. 2015;25(10):592–600.
- Bury M, Le Calvé B, Ferbeyre G, Blank V, Lessard F. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy. Trends Cell Biol. 2021;31(5):331–344.
- Ding L, Cao J, Lin W, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci 2020, Vol 21, Page 1960. 2020;21(6):1960.
- Swaffer MP, Jones AW, Flynn HR, Snijders AP, Nurse P. CDK Substrate Phosphorylation and Ordering the Cell Cycle. Cell. 2016;167(7):1750–1761.e16.
- Izadi S, Nikkhoo A, Hojjat-Farsangi M, et al. CDK1 in Breast Cancer: Implications for Theranostic Potential. Anticancer Agents Med Chem. 2020;20(7):758–767.
- Li M, He F, Zhang Z, Xiang Z, Hu D. CDK1 serves as a potential prognostic biomarker and target for lung cancer. J Int Med Res. 2020;48(2).
- Sofi S, Mehraj U, Qayoom H, et al. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors. Med Oncol. 2022;39(9):1–15.
- Mouna R, Broisat A, Ahmed A, et al. Antiproliferative activity, cell-cycle arrest, apoptotic induction and LCHRMS/MS analyses of extracts from two Linum species. Pharm Biol. 2022;60(1):1491–1501.
- Mouna R, Broisat A, Debiossat M, Boumendjel A, Ghezzi C, Kabouche Z. Evaluation of antiproliferative activity, apoptotic induction and LC-HRMS/MS analyses of the VLC fractions of L. numidicum. Nat Prod Res. 2023;37(5):788–792.
- Mouna R, Kabouche Z, Bensouici C, Broisat A, Ahmed A, Ghezzi C. Phytochemical profiling and antioxidant activity of Linum trigynum. Nat Prod Res. 2024;38(10):1780–1785.
- Naumenko-Svetlova AA, A. H-CA. Chemical composition and biological activity of wild Linum (Linaceae) Species. Rastit Resur. 2024;60(1):21–53.
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2018 181. 2018;18(1):41–58.
- Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today. 2015;20(3):318–331.
- Warren GL, Andrews CW, Capelli AM, et al. A critical assessment of docking programs and scoring functions. J Med Chem. 2006;49(20):5912–5931.
- Sun Z, Duke SH, Henson CA. The Role of Pea Chloroplast [alpha]-Glucosidase in Transitory Starch Degradation. Plant Physiol. 1995;108(1):211–217.
- Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Reports 2017 71. 2017;7(1):1–13.
- Marko D, Schätzle S, Friedel A, et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 2001 842. 2001;84(2):283–289.
- Raghavan P, Tumati V, Yu L, et al. AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells. Int J Radiat Oncol. 2012;84(4):e507–e514.
- Thomas HD, Wang LZ, Roche C, et al. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. Eur J Cancer. 2011;47(13):2052–2059.
- Zhang M, Zhang L, Hei R, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913.
- Zhang W, Liu C, Li J, et al. Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer. 2020 August 7 Epub.
- Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009 93. 2009;9(3):153–166.
- McGann M. FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des. 2012;26(8):897–906.
- Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43(20):3714–3717.
- Rendic SP, Guengerich FP. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Arch Toxicol 2021 952. 2021;95(2):395–472.
- Corbeil CR, Williams CI, Labute P. Variability in docking success rates due to dataset preparation. J Comput Aided Mol Des. 2012;26(6):775–786.
- Su M, Yang Q, Du Y, et al. Comparative Assessment of Scoring Functions: The CASF-2016 Update. J Chem Inf Model. 2019;59(2):895–913.
- Kooistra AJ, Kanev GK, Van Linden OPJ, Leurs R, De Esch IJP, De Graaf C. KLIFS: a structural kinase-ligand interaction database. Nucleic Acids Res. 2016;44(D1):D365–D371.
- Wang R, Fang X, Lu Y, Wang S. The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem. 2004;47(12):2977–2980.
- Patel Y, Dixit N, Patel SK. Uncovering hub genes and screening of natural CDK1 inhibitors for targeting in hepatocellular carcinoma. 2025 January 1 Epub.
- Mapelli M, Massimiliano L, Crovace C, et al. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem. 2005;48(3):671–679.
- Rathod S, Shinde K, Porlekar J, et al. Computational Exploration of Anti-cancer Potential of Flavonoids against Cyclin-Dependent Kinase 8: An In Silico Molecular Docking and Dynamic Approach. ACS Omega. 2023;8(1):391–409.
- Brown NR, Korolchuk S, Martin MP, et al. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun 2015 61. 2015;6(1):1–12.
- Navarro-Retamal C, Caballero J. Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship. PLoS One. 2016;11(8):e0161111.
- Liu T, Xu Z, He Q, Chen Y, Yang B, Hu Y. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: Design, synthesis, and biological evaluation. Bioorg Med Chem Lett. 2007;17(1):278–281.
- García-Sosa AT, Siid S, Maran U. Design of multibinding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model. 2008;48(10):2074–2080.
- Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9(8):2344–2353.
- Zhao C, He Y, Shi H, et al. Investigating the molecular mechanism of vitexin targeting CDK1 to inhibit colon cancer cell proliferation via GEO chip data mining, computer simulation, and biological activity verification. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(2):1637–1652.
- Roskoski R. Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. 2021 July 1 Epub.
- Sahu VK, Khan AKR, Singh RK, Singh PP. Hydrophobic, Polar and Hydrogen Bonding Based Drug-Receptor Interaction of Tetrahydroimidazobenzodiazepinones. Am J Immunol. 2008;4(3):33–42.
- Rupniak NMJ, Williams AR. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol. 1994;265(3):179–183.
- Thorson JS, Chapman E, Schultz PG. Analysis of Hydrogen Bonding Strengths in Proteins Using Unnatural Amino Acids. J Am Chem Soc. 1995;117(36):9361–9362.
Language: English
Page range: 67 - 78
Submitted on: Sep 16, 2025
Accepted on: Jan 13, 2026
Published on: Jun 1, 2026
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Ryma Mouna, Abdalwahab Ahmed, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.